Key result
Outpatient sotalol initiation shows no significant QTc change at one month with few adverse events.
Why the study?
Sotalol is conventionally initiated in an inpatient setting to monitor for QTc prolongation and fatal arrhythmias, prompting an assessment of the safety of outpatient initiation.
Does outpatient initiation of sotalol safely prevent significant QTc prolongation in patients with arrhythmias?
Meta-Analysis (n=1,248)
Does outpatient initiation of sotalol safely prevent significant QTc prolongation in patients with arrhythmias?
Standardized Mean Difference: 0.152 (95% CI -0.354–0.657)
p-value: p=0.557
Outpatient initiation of sotalol appears safe with no significant change in QTc interval at one month, potentially challenging the conventional requirement for inpatient initiation.
May support outpatient sotalol initiation in selected patients; leaves open confirmation in prospective RCTs.
Background/Introduction Sotalol is a class III anti-arrhythmic medication commonly used in maintaining sinus rhythm in patients with arrhythmias, most notably atrial fibrillation. Sotalol is conventionally initiated in an inpatient setting (typically three days) to allow close monitoring of its effects, particularly corrected QT interval (QTc) prolongation, which may predispose patients to fatal arrhythmias such as torsades de pointes. Purpose In this meta-analysis, we aim to assess the safety of initiating sotalol in an outpatient setting. Methods We searched PubMed, Embase, Scopus, Web of Science and the Cochrane library for observational studies and randomized controlled trials assessing the safety of outpatient initiation of sotalol until February 2025. Our primary endpoint was the change from baseline in QTc interval at one month. Our secondary endpoints included the rates of adverse events after sotalol initiation. Standardized mean differences from baseline in QTc interval with 95% confidence intervals were pooled with a random-effects model using CMA V3 software. Results We included three observational studies with a total cohort of 1248 patients. The baseline characteristics of included studies are summarized in figure 1. At one month post sotalol initiation in an outpatient setting, there was no statistically significant change in QTc interval from baseline ( SMD = 0.152, 95% CI = -0.354 to 0.657, p = 0.557, I^2= 98% ) as illustrated in figure 2. The most frequent adverse events were bradycardia and fatigue with a very low incidence of QTc prolongation requiring discontinuation of the drug. Conclusion The initiation of Sotalol in an outpatient setting appears to be safe and associated with no significant adverse events. Although these results are promising, large randomized controlled trials are warranted to establish the safety and efficacy of outpatient initiation of sotalol.Figure 1:Baseline Characteristics Figure 2:QTc Change from Baseline.
No takes yet. Share an insight, caveat, or question.
Shelig et al. (2025) conducted a meta-analysis in Arrhythmias (atrial fibrillation) (n=1,248). Outpatient sotalol initiation vs. Baseline was evaluated on change from baseline in QTc interval at one month (SMD 0.152, 95% CI -0.354 to 0.657, p=0.557). Outpatient initiation of sotalol was not associated with a statistically significant change in QTc interval from baseline at one month (SMD 0.152; 95% CI -0.354 to 0.657; p=0.557).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: